Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03801525. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects With Chronic Lymphocytic Leukemia (CLL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
ULTRA-V: Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL)
Study identification
- NCT ID
- NCT03801525
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 277 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 16, 2019 (Actual)
- Primary completion
- Dec 20, 2022 (Actual)
- Completion
- Dec 20, 2022 (Actual)
- Last update posted
- Apr 19, 2024
2019 – 2022
United States locations
- U.S. sites
- 50
- U.S. states
- 29
- U.S. cities
- 48
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| TG Therapeutics Investigational Trial Site | Birmingham | Alabama | 35294 | — |
| TG Therapeutics Investigational Trial Site | Huntsville | Alabama | 35805 | — |
| TG Therapeutics Investigational Trial Site | Tucson | Arizona | 85711 | — |
| TG Therapeutics Investigational Trial Site | Duarte | California | 91010 | — |
| TG Therapeutics Investigational Trial Site | La Jolla | California | 92093 | — |
| TG Therapeutics Investigational Trial Site | Aurora | Colorado | 80012 | — |
| TG Therapeutics Investigational Trial Site | Stamford | Connecticut | 06904 | — |
| TG Therapeutics Investigational Trial Site | Boca Raton | Florida | 33486 | — |
| TG Therapeutics Investigational Trial Site | Fort Myers | Florida | 33901 | — |
| TG Therapeutics Investigational Trial Site | Jacksonville | Florida | 32224 | — |
| TG Therapeutics Investigational Trial Site | St. Petersburg | Florida | 33705 | — |
| TG Therapeutics Investigational Trial Site | Tampa | Florida | 33612 | — |
| TG Therapeutics Investigational Trial Site | Atlanta | Georgia | 30322 | — |
| TG Therapeutics Investigational Trial Site | Decatur | Illinois | 62526 | — |
| TG Therapeutics Investigational Trial Site | Niles | Illinois | 60714 | — |
| TG Therapeutics Investigational Site | Peoria | Illinois | 61615 | — |
| TG Therapeutics Investigational Trial Site | Fort Wayne | Indiana | 46804 | — |
| TG Therapeutics Investigational Trial Site | Indianapolis | Indiana | 46237 | — |
| TG Therapeutics Investigational Trial Site | Des Moines | Iowa | 50309 | — |
| TG Therapeutics Investigational Trial Site | Westwood | Kansas | 66210 | — |
| TG Therapeutics Investigational Site | Louisville | Kentucky | 40207 | — |
| TG Therapeutics Investigational Trial Site | Bethesda | Maryland | 37210 | — |
| TG Therapeutics Investigational Trial Site | Columbia | Maryland | 21044 | — |
| TG Therapeutics Investigational Trial Site | Ann Arbor | Michigan | 48197 | — |
| TG Therapeutics Investigational Trial Site | Detroit | Michigan | 48201 | — |
| TG Therapeutics Investigational Trial Site | Detroit | Michigan | 48202 | — |
| TG Therapeutics Investigational Trial Site | Rochester | Minnesota | 55905 | — |
| TG Therapeutics Investigational Trial Site | Omaha | Nebraska | 68198 | — |
| TG Therapeutics Investigational Trial Site | Lebanon | New Hampshire | 03756 | — |
| TG Therapeutics Investigational Trial Site | Hackensack | New Jersey | 07601 | — |
| TG Therapeutics Investigational Trial Site | Morristown | New Jersey | 07960 | — |
| TG Therapeutics Investigational Trial Site | New York | New York | 10065 | — |
| TG Therapeutics Investigational Trial Site | Charlotte | North Carolina | 28204 | — |
| TG Therapeutics Investigational Trial Site | Columbus | Ohio | 43210 | — |
| TG Therapeutics Investigational Trial Site | Eugene | Oregon | 97401 | — |
| TG Therapeutics Investigational Trial Site | Philadelphia | Pennsylvania | 19106 | — |
| TG Therapeutics Investigational Trial Site | Charleston | South Carolina | 29414 | — |
| TG Therapeutics Investigational Trial Site | Greenville | South Carolina | 29616 | — |
| TG Therapeutics Investigational Trial Site | Chattanooga | Tennessee | 37404 | — |
| TG Therapeutics Investigational Trial Site | Knoxville | Tennessee | 37916 | — |
| TG Therapeutics Investigational Trial Site | Nashville | Tennessee | 37203 | — |
| TG Therapeutics Investigational Trial Site | Austin | Texas | 78705 | — |
| TG Therapeutics Investigational Trial Site | San Antonio | Texas | 78229 | — |
| TG Therapeutics Investigational Trial Site | Tyler | Texas | 75702 | — |
| TG Therapeutics Investigational Trial Site | Ogden | Utah | 84405 | — |
| TG Therapeutics Investigational Trial Site | Salt Lake City | Utah | 84106 | — |
| TG Therapeutics Investigational Trial Site | Blacksburg | Virginia | 24060 | — |
| TG Therapeutics Investigational Trial Site | Gainesville | Virginia | 20155 | — |
| TG Therapeutics Investigational Trial Site | Seattle | Washington | 98104 | — |
| TG Therapeutics Investigational Trial Site | Seattle | Washington | 98108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03801525, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2024 · Synced Nov 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.